<DOC>
	<DOCNO>NCT00410540</DOCNO>
	<brief_summary>The purpose study demonstrate clinical equivalence hydromorphone morphine ( immediate-release [ IR ] sustained-release [ SR ] formulation ) use `` bad pain past 24 hour '' item Brief Pain Inventory ( BPI ) . The secondary objective study compare hydromorphone morphine follow variable : pain measure , various questionnaire , safety tolerability variable .</brief_summary>
	<brief_title>A Study OROS Hydromorphone HCL v Morphine Cancer Pain Patients .</brief_title>
	<detailed_description>This phase-3 , multicenter , multinational , randomize ( patient assign different treatment base chance ) , active-controlled , double-blind , multiple-ascending-dose , parallel-group study adult patient cancer pain receive and/or require strong oral transdermal opioid analgesic ( 60-540 mg oral morphine equivalent daily ) . This study consist 2 phase : initial immediate release ( IR ) phase subsequent slow release ( SR ) phase . Eligible patient randomize 1:1 receive either OROS hydromorphone HCl morphine sulfate ( immediate release formulation immediate release phase , slow release formulation slow release phase ) . In immediate release phase ( 2-9 day ) , patient start appropriate initial dose immediate release medication every 4 hour ( q4h ) , ( 6 doses/day ) use 5:1 conversion ratio ( morphine equivalent : hydromorphone dosage ) . If patient great 3 breakthrough-pain episode require additional pain medication 24 hour , study medication dosage increase , day . When patient achieve dose-stable pain control ( 2 day 3 less 3 breakthrough-pain episode per day ) , patient permit continue slow release phase . The patient give equivalent dosage slow release formulation drug ( OROSÂ® hydromorphone HCL day morphine sulfate slow release two time per day ) , administer use double-dummy technique . Dosage increase permit every 2 day patient 3 breakthrough-pain episode 24 hour . To complete slow release phase , patient achieve dose-stable pain control least 2 days.Safety assessment physical examination , labs adverse event report do . OROS hydromorphone HCL slow release 8 , 16 , 32 , 64mg tablet ; Morphine sulfate immediate release10 , 20 , 50 mg capsule ; Morphine sulfate slow release 5 , 30 , 60 , 90 , 120 , 160 , 200mg capsule ; hydromorphone immediate release 2 , 4 , 8 mg ; The immediate release medication orally every 4 hour ; The OROS hydromorphone slow release formulation orally every 24 hour morphine slow release orally twice daily .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Patients cancer pain currently receive strong oral transdermal opioid analgesic strong opioid analgesic appropriate Patients require expect require 60 540 mg oral morphine morphine equivalent every 24 hour chronic management cancer pain Patients pain suitable treatment oncedaily formulation Patients concomitant chemotherapy radiotherapy . Patient gastrointestinal ( GI ) disease sufficient severity interfere orally administer analgesia ( eg dysphagia , vomit , constipation , bowel obstruction , severe gut narrow ) permit enroll Patient risk treatment morphine hydromorphone outweigh potential benefit raise intracranial pressure , hypotension , hypothyroidism , asthma , reduce respiratory reserve , prostatic hypertrophy , hepatic renal impairment , convulsive disorder , Addison 's disease Debilitated patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>Oral analgesic</keyword>
	<keyword>OROS hydromorphone HCL</keyword>
	<keyword>Morphine sulfate</keyword>
</DOC>